Physician profile
Anne L Ford
NPI 1649398736
$4,596.79
in general payments reported to CMS, 2019-2025
33 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $130 · 2021: $459 · 2022: $929 · 2023: $948 · 2024: $534 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $526.57 | 2019-2025 | |
| Boston Scientific Corporation | $517.23 | 2019-2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $491.32 | 2019-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $396.46 | 2019-2023 | Farxiga, Brilinta |
| Biosense Webster, INC. | $380.33 | 2025 | Carto 3, Qdot Micro, Soundstar |
| Janssen Pharmaceuticals, INC | $339.91 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $313.33 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.32 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $125.69 | 2019-2022 | |
| Novo Nordisk INC | $125.41 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $110.00 | 2019-2024 | Repatha |
| Esperion Therapeutics, INC. | $99.90 | 2022 | |
| Abbott Laboratories | $93.62 | 2019-2023 | Confirm Rx |
| Lexicon Pharmaceuticals, INC. | $92.65 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $82.10 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $76.87 | 2019-2023 | Definity |
| Regeneron Healthcare Solutions, INC. | $73.09 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.11 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $49.64 | 2024 | Arcalyst |
| Lundbeck LLC | $43.14 | 2019 | |
| Altathera Pharmaceuticals LLC | $36.85 | 2023-2024 | Sotalol Hydrochloride |
| Astellas Pharma US INC | $34.88 | 2019 | |
| Daiichi Sankyo INC. | $33.60 | 2019-2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $30.47 | 2023-2024 | Opsumit, Uptravi |
| Edwards Lifesciences Corporation | $28.67 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Baxter Healthcare | $24.94 | 2025 | Hillrom - Q-Stress Cardiac Stress Testing System |
| Melinta Therapeutics, LLC | $18.77 | 2019 | |
| Lilly USA, LLC | $16.85 | 2025 | Mounjaro, Zepbound |
| Vifor Pharma, INC. | $16.49 | 2020 | |
| Medtronic Vascular, INC. | $15.85 | 2019 | |
| Chiesi USA, INC. | $15.47 | 2020 | |
| Merck Sharp & Dohme LLC | $15.41 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.85 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.